Showing 2601-2610 of 3153 results for "".
- Investigational Atopic Dermatitis Cream Disappoints in Phase II Trialhttps://practicaldermatology.com/news/investigational-atopic-dermatitis-cream-disappoints-in-phase-ii-trial/2459003/Results from a phase II trial do not bode well for the future of the investigational atopic dermatitis cream MRX-6. The double-blind, parallel-group, vehicle-controlled study evaluated the safety and efficacy of MRX-6 cream 2% among 73 children suffering from mild-to-moderate atopic dermatitis. P
- Ichthyosis Patient Raising Awareness, Funds with Hikehttps://practicaldermatology.com/news/20140531-ichthyosis_patient_raising_awareness_funds_with_hike/2459223/To raise awareness of ichthysosis and funds for research, Brian Gass of St. Louis is hiking the Pacific Crest Trail – 2,600 miles from Mexico to Canada, crossing the Sierras, over about 110 days. The 21-year-old college student has the rare genetic skin disease, as do three siblings. The experienced
- Injectable Methotrexate Product Now Availablehttps://practicaldermatology.com/news/20140117-injectable_methotrexate_product_now_available/2459369/For patients who do not tolerate oral methotrexate for psoriasis, a new recently approved injectable methotrexate product is now available from Antares Pharma. Approved in October 2013 for the subcutaneous methotrexate product for once weekly self-administration, Otrexup is indicated for use in adul
- Some Patients Apply Sunscreen to Nevi Onlyhttps://practicaldermatology.com/news/20130225-some_patients_apply_sunscreen_to_nevi_only/2459610/An unexpected number of patients with nevi report that they selectively apply sunscreens to moles only, and almost half of them say that a dermatologist told them to do so, according to a new study. (J Eur Acad Dermatol Venereol. e-pub). Of 1,816 European subjects surveyed (59.3% females, age 14-90
- Acne Incidence Higher with Higher-Dose LNG-IUS, Meta-Analysis Findshttps://practicaldermatology.com/news/acne-incidence-higher-with-higher-dose-lng-ius-meta-analysis-finds/2485045/A new systematic review and meta-analysis shows the incidence of acne among users of the levonorgestrel-releasing intrauterine system (LNG-IUS), identifying both dosage and age as influential factors. The review included nine ra
- Vixarelimab Shows Dose-Dependent Efficacy in Prurigo Nodularis Phase 2b Trialhttps://practicaldermatology.com/news/vixarelimab-shows-dose-dependent-efficacy-in-prurigo-nodularis-phase-2b-trial/2484982/Vixarelimab demonstrated dose-dependent improvements in itch severity and skin lesion clearance in patients with moderate to severe prurigo nodularis (PN), according to new results from a phase 2b randomized clinical trial. Res
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- Biosimilar STEQEYMA Now Approved for All Ustekinumab Dosage Forms, Strengthshttps://practicaldermatology.com/news/Biosimilar-STEQEYMA-Now-Approved-All-Ustekinumab-Dosage-Forms-Strengths/2475172/The US Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection, according to a press release from Celltrion, Inc. The additional pre
- Analysis: Methotrexate Does Not Enhance Adalimumab Outcomes in Psoriasishttps://practicaldermatology.com/news/methotrexate-does-not-enhance-adalimumab-outcomes-in-psoriasis/2475072/Concomitant methotrexate does not improve the effectiveness or persistence of adalimumab in plaque psoriasis, according to findings from a new study. Researchers investigating whether methotrexate enhances adalimumab’s durab
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).